血清胃蛋白酶原II在治疗幽门螺杆菌感染中的临床应用性

• 作 者: Di Mario F. Moussa A.M.o L.G. 徐小洁
• 机 构: Department of Clinical Science, Via Gramsci 14, IT-43100 Parma, Italy
• 出 处: 世界核心医学期刊文摘(胃肠病学分册)
• 发表日期: 2005年06期
• 关键词: 血清胃蛋白酶原 临床应用性 幽门 螺杆 胃镜检查 消化不良症状 阴性 界值 基线 特异性

Background: Serum pepsinogen II (sPGII) levels are known to increase during Helicobacter pylori infection. Aim: To assess H. pylori infection and success of H. pylori therapy by means of sPGII levels. Methods: sPGII levels were determined in 156 H. pylori-positive and 157 H. pylori-negative consecutive patients with dyspeptic symptoms. Additionally, sPGII determination was performed in 70 H. pylori-positive patients 2 months after H. pylori eradication therapy. In 29 of these 70 patients, gastroscopy was performed to evaluate the effect of H. pylori therapy on gastric activity. Results: H. pyloripositive subjects demonstrated a significantly higher mean of sPGII levels than H. pylori-negative subjects (16.8 ±7.4 vs. 8.6 ±3.7 μg/l; p < 0.001). The best sPGII cut-off for predicting H. pylori infection was 9.93 μg/l (sensitivity 83%, specificity 73%). The best cut-off values to evaluate success of therapy were: sPGII of 9.47 μg/l, a sPGII variation level (difference between baseline and after therapy) of 4.54 μg/l, and a sPGIIΔvalue (sPGII variation divided by sPGII before therapy) of 25%(sensitivity 93%, specificity 91%). Conclusions: sPGII levels may be used as a reliable marker of H. pylori infection in the initial diagnosis as well as to evaluate H. pylori eradication and subsequent changes in gastric inflammation.

Aim: To evaluate H. pylori infection and success of H. pylori therapy by means of sPGII levels. Methods: sPGII levels were determined in 156 H. pylori (sPGII) levels are known to increase during Helicobacter pylori infection. -positive and 157 H. pylori-negative consecutive patients with dyspeptic symptoms. Additionally, sPGII determination was performed in 70 H. pylori-positive patients 2 months after H. pylori eradication therapy. In 29 of these 70 patients, gastroscopy was performed to evaluate the effect of H. pylori therapy on gastric activity. Results: H. pylori -positive subjects demonstrated a significantly higher mean of sPGII levels than H. pylori-negative subjects (16.8 ± 7.4 vs. 8.6 ± 3.7 μg / l; p <0.001 The best sPGII cut-off for predicting H. pylori infection was 9.93 μg / l (sensitivity 83% specificity 73%). The best cut-off values ​​to evaluate success of therapy were: sPGII of 9.47 μg / l, a sPGII variation level (difference between baseli ne and after therapy) of 4.54 μg / l, and a sPGII variation (by sPGII before therapy) of 25% (sensitivity 93%, specificity 91%). pylori infection in the initial diagnosis as well as to evaluate H. pylori eradication and subsequent changes in gastric inflammation.